{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:32:31Z","timestamp":1790937151534,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI152533"],"award-info":[{"award-number":["R01 AI152533"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI152551"],"award-info":[{"award-number":["R01 AI152551"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1054480"],"award-info":[{"award-number":["OPP1054480"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203134\/Z\/16\/Z"],"award-info":[{"award-number":["203134\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["R01 AI50234"],"award-info":[{"award-number":["R01 AI50234"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["R01 AI124678"],"award-info":[{"award-number":["R01 AI124678"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.pt.2021.01.009","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T08:16:42Z","timestamp":1614327402000},"page":"493-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["MalDA, Accelerating Malaria Drug Discovery"],"prefix":"10.1016","volume":"37","author":[{"given":"Tuo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Ottilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva S.","family":"Istvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla P.","family":"Godinez-Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Lukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Baraga\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Walpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquin C.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chibale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen J.","family":"Dechering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Llin\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus C.S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wyllie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Case W.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Gamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fidock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyann F.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Winzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2021.01.009_bb0005","series-title":"World Malaria Report 2020: 20 Years of Global Progress and Challenges","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.pt.2021.01.009_bb0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1475-2875-10-S1-S3","article-title":"Natural products as starting points for future anti-malarial therapies: going back to our roots?","volume":"10","author":"Wells","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.01.009_bb0015","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature12051","article-title":"High-level semi-synthetic production of the potent antimalarial artemisinin","volume":"496","author":"Paddon","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0020","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/jm901473s","article-title":"The structure\u2212activity relationship of the antimalarial ozonide Arterolane (OZ277)","volume":"53","author":"Dong","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.actatropica.2014.12.005","article-title":"Efficacy of Synriam\u2122, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni","volume":"143","author":"Mossallam","year":"2015","journal-title":"Acta Trop."},{"key":"10.1016\/j.pt.2021.01.009_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2021.01.009_bb0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature09099","article-title":"Chemical genetics of Plasmodium falciparum","volume":"465","author":"Guiguemde","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nature09107","article-title":"Thousands of chemical starting points for antimalarial lead identification","volume":"465","author":"Gamo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0050","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1073\/pnas.0802982105","article-title":"In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen","volume":"105","author":"Plouffe","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat9446","article-title":"Open-source discovery of chemical leads for next-generation chemoprotective antimalarials","volume":"362","author":"Antonova-Koch","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.01.009_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05777-2","article-title":"A high throughput screen for next-generation leads targeting malaria parasite transmission","volume":"9","author":"Delves","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0065","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/AAC.02727-13","article-title":"KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission","volume":"58","author":"Kuhen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.01.009_bb0070","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.1211936","article-title":"Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery","volume":"334","author":"Meister","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.01.009_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15440-4","article-title":"Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway","volume":"11","author":"LaMonte","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0080","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/AAC.03478-14","article-title":"A first-in-human randomized, double-blind, placebo-controlled, single-and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers","volume":"58","author":"Leong","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.01.009_bb0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nchembio.211","article-title":"Design, synthesis and selection of DNA-encoded small-molecule libraries","volume":"5","author":"Clark","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0090","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1021\/acs.jmedchem.5b01898","article-title":"DNA-encoded library screening identifies benzo [b][1,4] oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors","volume":"59","author":"Harris","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0095","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1021\/acs.jmedchem.9b01782","article-title":"DNA-encoded library screening as core platform technology in drug discovery: its synthetic method development and applications in DEL synthesis","volume":"63","author":"Song","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.01.009_bb0105","doi-asserted-by":"crossref","first-page":"16823","DOI":"10.1073\/pnas.1204556109","article-title":"Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target","volume":"109","author":"Yuthavong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0110","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/bcp.14219","article-title":"First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection","volume":"86","author":"Chughlay","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2021.01.009_bb0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/acsinfecdis.7b00276","article-title":"Using in vitro evolution and whole-genome analysis to discover next generation targets for antimalarial drug discovery","volume":"4","author":"Luth","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2021.01.009_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/science.aap7847","article-title":"Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis","volume":"360","author":"Zhang","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.01.009_bb0125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2017.06.030","article-title":"Functional profiling of a Plasmodium genome reveals an abundance of essential genes","volume":"170","author":"Bushell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pt.2021.01.009_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms5052","article-title":"A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains","volume":"5","author":"Preston","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.aan4472","article-title":"Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics","volume":"359","author":"Cowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.01.009_bb0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chembiol.2020.01.001","article-title":"The antimalarial natural product salinipostin A identifies essential \u03b1\/\u03b2 serine hydrolases involved in lipid metabolism in P. falciparum parasites","volume":"27","author":"Yoo","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003293","article-title":"Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families","volume":"9","author":"Bopp","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.pt.2021.01.009_bb0150","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1101\/gr.203711.115","article-title":"Indels, structural variation, and recombination drive genomic diversity in Plasmodium falciparum","volume":"26","author":"Miles","year":"2016","journal-title":"Genome Res."},{"key":"10.1016\/j.pt.2021.01.009_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003375","article-title":"Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications","volume":"9","author":"Guler","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2021.01.009_bb0160","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1073\/pnas.1011560108","article-title":"Validation of isoleucine utilization targets in Plasmodium falciparum","volume":"108","author":"Istvan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/bfgp\/elz012","article-title":"Cutting back malaria: CRISPR\/Cas9 genome editing of Plasmodium","volume":"18","author":"Lee","year":"2019","journal-title":"Brief. Funct. Genom."},{"key":"10.1016\/j.pt.2021.01.009_bb0170","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nmeth.3063","article-title":"Efficient CRISPR-Cas9-mediated genome editing in Plasmodium falciparum","volume":"11","author":"Wagner","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.pt.2021.01.009_bb0175","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nbt.2925","article-title":"Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system","volume":"32","author":"Ghorbal","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.pt.2021.01.009_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10727","article-title":"Synthetic RNA\u2013protein modules integrated with native translation mechanisms to control gene expression in malaria parasites","volume":"7","author":"Ganesan","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms6329","article-title":"Versatile control of Plasmodium falciparum gene expression with an inducible protein\u2013RNA interaction","volume":"5","author":"Goldfless","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0190","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40529","article-title":"Plasmodium Niemann\u2013Pick type C1-related protein is a druggable target required for parasite membrane homeostasis","volume":"8","author":"Istvan","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.pt.2021.01.009_bb0195","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.aan1478","article-title":"Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion","volume":"358","author":"Nasamu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.01.009_bb0200","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.chembiol.2020.04.001","article-title":"Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity","volume":"27","author":"Vanaerschot","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0205","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.str.2016.06.018","article-title":"Dimerization of arginyl-tRNA synthetase by free heme drives its inactivation in Plasmodium falciparum","volume":"24","author":"Jain","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.pt.2021.01.009_bb0210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.molbiopara.2013.04.007","article-title":"Crystal structures of Plasmodium falciparum cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design","volume":"189","author":"Koh","year":"2013","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2021.01.009_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/srep27531","article-title":"Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed death in Plasmodium falciparum","volume":"6","author":"Pasaje","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2021.01.009_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3575","article-title":"The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs","volume":"7","author":"Herman","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.01.009_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms1522","article-title":"Malaria parasite tyrosyl-tRNA synthetase secretion triggers pro-inflammatory responses","volume":"2","author":"Bhatt","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0230","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature19804","article-title":"Diversity-oriented synthesis yields novel multistage antimalarial inhibitors","volume":"538","author":"Kato","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aas9917","article-title":"Antimalarial pantothenamide metabolites target acetyl\u2013coenzyme A biosynthesis in Plasmodium falciparum","volume":"11","author":"Schalkwijk","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.01.009_bb0240","first-page":"476","article-title":"Identification of the Plasmodium falciparum acetyl-CoA synthetase as an emerging antiplasmodial drug target","volume":"101","author":"Summers","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.01.009_bb0245","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1128\/AAC.01224-16","article-title":"Metabolomic profiling of the malaria box reveals antimalarial target pathways","volume":"60","author":"Allman","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.01.009_bb0250","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.chembiol.2019.11.009","article-title":"Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery","volume":"27","author":"Murithi","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-015-0673-8","article-title":"Novel pantothenate derivatives for anti-malarial chemotherapy","volume":"14","author":"Pett","year":"2015","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.01.009_bb0260","doi-asserted-by":"crossref","first-page":"10190","DOI":"10.1074\/jbc.273.17.10190","article-title":"Transport and metabolism of the essential vitamin pantothenic acid in human erythrocytes infected with the malaria parasite Plasmodium falciparum","volume":"273","author":"Saliba","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9735","article-title":"Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase","volume":"9","author":"Paquet","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.01.009_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3174","article-title":"Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay","volume":"11","author":"Dziekan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.01.009_bb0275","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/acsinfecdis.9b00482","article-title":"Probing the Open Global Health Chemical Diversity Library for multistage-active starting points for next-generation antimalarials","volume":"6","author":"Abraham","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2021.01.009_bb0280","article-title":"MAIP: a prediction platform for predicting blood-stage malaria inhibitors","author":"Bosc","year":"2020","journal-title":"Res. Square"},{"key":"10.1016\/j.pt.2021.01.009_bb0285","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.cell.2020.08.015","article-title":"Structural basis for blocking sugar uptake into the malaria parasite Plasmodium falciparum","volume":"183","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pt.2021.01.009_bb0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-020-1963-z","article-title":"The molecular basis for sugar import in malaria parasites","volume":"578","author":"Qureshi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms11901","article-title":"A broad analysis of resistance development in the malaria parasite","volume":"7","author":"Corey","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0300","doi-asserted-by":"crossref","first-page":"133","DOI":"10.15252\/emmm.201607295","article-title":"How to tackle antimalarial resistance?","volume":"9","author":"Leroy","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.pt.2021.01.009_bb0305","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00696-16","article-title":"Mutations in the Plasmodium falciparum cyclic amine resistance locus (PfCARL) confer multidrug resistance","volume":"7","author":"LaMonte","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.pt.2021.01.009_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.166","article-title":"UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes","volume":"1","author":"Lim","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.pt.2021.01.009_bb0315","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/acsinfecdis.6b00025","article-title":"Plasmodium falciparum cyclic amine resistance locus (PfCARL), a resistance mechanism for two distinct compound classes","volume":"2","author":"Magistrado","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2021.01.009_bb0320","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.chom.2012.04.015","article-title":"Selective and specific inhibition of the Plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin","volume":"11","author":"Hoepfner","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pt.2021.01.009_bb0325","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis","volume":"116","author":"Baraga\u00f1a","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0330","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrm2468","article-title":"Diversity of degradation signals in the ubiquitin\u2013proteasome system","volume":"9","author":"Ravid","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0335","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1021\/acs.jmedchem.7b00671","article-title":"Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity","volume":"60","author":"LaMonte","year":"2017","journal-title":"J. Medic. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0340","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature16936","article-title":"Structure-and function-based design of Plasmodium-selective proteasome inhibitors","volume":"530","author":"Li","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0345","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1021\/acs.jmedchem.8b01161","article-title":"Target validation and identification of novel boronate inhibitors of the Plasmodium falciparum proteasome","volume":"61","author":"Xie","year":"2018","journal-title":"J. Medic Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007722","article-title":"Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents","volume":"15","author":"Stokes","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2021.01.009_bb0355","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41564-019-0524-4","article-title":"The structure of the PA28\u201320S proteasome complex from Plasmodium falciparum and implications for proteostasis","volume":"4","author":"Xie","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.pt.2021.01.009_bb0360","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrmicro3523","article-title":"Cooperative development of antimicrobials: looking back to look ahead","volume":"13","author":"Nathan","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2021.01.009_bb0365","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.01.009_bb0370","first-page":"226","article-title":"Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy","volume":"10","author":"Phillips","year":"2010","journal-title":"Infect. Disord. Drug Targets (formerly Curr. Drug Targets Infect. Disord.)"},{"key":"10.1016\/j.pt.2021.01.009_bb0375","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acsinfecdis.6b00144","article-title":"A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria","volume":"2","author":"Phillips","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2021.01.009_bb0380","doi-asserted-by":"crossref","first-page":"33054","DOI":"10.1074\/jbc.M110.162081","article-title":"Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model","volume":"285","author":"Booker","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0385","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/ml200143c","article-title":"Optimization of potent inhibitors of P. falciparum dihydroorotate dehydrogenase for the treatment of malaria","volume":"2","author":"Skerlj","year":"2011","journal-title":"ACS Medic. Chem. Lett."},{"key":"10.1016\/j.pt.2021.01.009_bb0390","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/acsmedchemlett.7b00030","article-title":"Discovery of antimalarial Azetidine-2-carbonitriles that inhibit P. falciparum dihydroorotate dehydrogenase","volume":"8","author":"Maetani","year":"2017","journal-title":"ACS Medic. Chem. Lett."},{"key":"10.1016\/j.pt.2021.01.009_bb0395","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1021\/cb200105d","article-title":"A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor","volume":"6","author":"Nam","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0400","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.chembiol.2011.09.016","article-title":"Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors","volume":"18","author":"Dong","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0405","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1016\/j.bmcl.2011.07.044","article-title":"Potent antimalarial 4-pyridones with improved physico-chemical properties","volume":"21","author":"Bueno","year":"2011","journal-title":"Bioorg. Medic. Chem. Lett."},{"key":"10.1016\/j.pt.2021.01.009_bb0410","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/infdis\/jiu565","article-title":"Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors","volume":"211","author":"Lukens","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2021.01.009_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005029","article-title":"Quinolone-3-diarylethers: a new class of antimalarial drug","volume":"5","author":"Nilsen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.01.009_bb0420","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/cb500616x","article-title":"Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials","volume":"10","author":"Flannery","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0425","doi-asserted-by":"crossref","first-page":"E5455","DOI":"10.1073\/pnas.1414221111","article-title":"(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium","volume":"111","author":"Jim\u00e9nez-D\u00edaz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0430","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","article-title":"Spiroindolones, a potent compound class for the treatment of malaria","volume":"329","author":"Rottmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.01.009_bb0435","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(19)30611-5","article-title":"Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a\/b trial","volume":"20","author":"Gaur","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2021.01.009_bb0440","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1021\/jm200694q","article-title":"Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr)","volume":"54","author":"Behrendt","year":"2011","journal-title":"J. Medic. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0445","doi-asserted-by":"crossref","first-page":"9109","DOI":"10.1073\/pnas.85.23.9109","article-title":"Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum","volume":"85","author":"Cowman","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0450","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1073\/pnas.85.23.9114","article-title":"Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria","volume":"85","author":"Peterson","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0455","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1073\/pnas.87.8.3014","article-title":"Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance","volume":"87","author":"Foote","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0460","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1073\/pnas.87.8.3018","article-title":"Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria","volume":"87","author":"Peterson","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0465","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature12782","article-title":"Targeting Plasmodium PI (4) K to eliminate malaria","volume":"504","author":"McNamara","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0470","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.01.009_bb0475","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.chembiol.2017.11.010","article-title":"Specific inhibition of the bifunctional farnesyl\/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site","volume":"25","author":"Gisselberg","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0480","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/cbdd.13170","article-title":"Remarkable similarity in Plasmodium falciparum and Plasmodium vivax geranylgeranyl diphosphate synthase dynamics and its implication for antimalarial drug design","volume":"91","author":"Venkatramani","year":"2018","journal-title":"Chem. Biol. Drug Design"},{"key":"10.1016\/j.pt.2021.01.009_bb0485","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1021\/acs.biochem.6b00398","article-title":"Dynamic structure and inhibition of a malaria drug target: geranylgeranyl diphosphate synthase","volume":"55","author":"Ricci","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.pt.2021.01.009_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/srep18429","article-title":"Single-target high-throughput transcription analyses reveal high levels of alternative splicing present in the FPPS\/GGPPS from Plasmodium falciparum","volume":"5","author":"Gabriel","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2021.01.009_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-12-184","article-title":"Cloning and characterization of bifunctional enzyme farnesyl diphosphate\/geranylgeranyl diphosphate synthase from Plasmodium falciparum","volume":"12","author":"Jord\u00e3o","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.01.009_bb0500","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.chembiol.2019.03.015","article-title":"Structure-guided identification of resistance breaking antimalarial N-myristoyltransferase inhibitors","volume":"26","author":"Schlott","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0505","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.molbiopara.2006.11.012","article-title":"Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase","volume":"152","author":"Eastman","year":"2007","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2021.01.009_bb0510","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1074\/jbc.M413556200","article-title":"Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum","volume":"280","author":"Eastman","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2021.01.009_bb0515","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cmdc.201200045","article-title":"Characterization of Plasmodium liver stage inhibition by halofuginone","volume":"7","author":"Derbyshire","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pt.2021.01.009_bb0520","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nchembio.790","article-title":"Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase","volume":"8","author":"Keller","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0525","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.chom.2020.02.005","article-title":"Dual Plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle","volume":"27","author":"Favuzza","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pt.2021.01.009_bb0530","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nsmb.3061","article-title":"Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes","volume":"22","author":"Hodder","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.pt.2021.01.009_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00572-x","article-title":"A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission","volume":"8","author":"Baker","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.01.009_bb0540","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau1682","article-title":"Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target","volume":"365","author":"Alam","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.01.009_bb0545","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1073\/pnas.1525670115","article-title":"Genetic resistance to purine nucleoside phosphorylase inhibition in Plasmodium falciparum","volume":"115","author":"Ducati","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.01.009_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms14574","article-title":"A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149222100012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149222100012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:53:21Z","timestamp":1778615601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149222100012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S147149222100012X"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2021.01.009","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MalDA, Accelerating Malaria Drug Discovery","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2021.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}